🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 7 of 28

  1. AU-011

    Aura Biosciences

    Non-muscle-invasive Bladder Cancer

    phase 1 small molecule active

    1 trial

  2. AVE0005 (aflibercept)

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 1 small molecule completed

    1 trial

  3. AVI-4126 Injection (RESTEN-NG®)

    Sarepta Therapeutics

    Neoplasms

    phase 1 small molecule completed

    1 trial

  4. AVN-944 capsules for oral administration

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Leukemia

    phase 1 small molecule completed

    1 trial

  5. AZD0530

    AstraZeneca

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  6. AZD2014 3 on/4 off & weekly paclitaxel

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  7. AZD3514

    AstraZeneca

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  8. AZD5363+Olaparib+Durvalumab

    Hospital Authority, Hong Kong

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  9. AZD6244

    AstraZeneca

    Neoplasms,

    phase 1 small molecule completed

    1 trial

  10. AZD7762

    AstraZeneca

    Cancer

    phase 1 small molecule terminated

    1 trial

  11. AZD9150

    IONIS PHARMACEUTICALS INC

    Advanced Adult Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  12. Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

    Eli Lilly Co.

    Prostatic Neoplasms

    phase 1 other active

    1 trial

  13. AdV-tk

    Candel Therapeutics

    Pancreatic Adenocarcinoma

    phase 1 mab completed

    1 trial

  14. Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

    United Therapeutics Europe Ltd

    Urothelial Carcinoma

    phase 1 mab active

    1 trial

  15. Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

    CytoMed Therapeutics Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  16. Aflibercept (AVE0005)

    Regeneron UK Limited

    Neoplasm Malignant

    phase 1 small molecule completed

    2 trials

  17. Alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    7 trials

  18. Alisertib

    Takeda

    B-cell Follicular Lymphoma

    phase 1 small molecule completed

    1 trial

  19. Alisertib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  20. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  21. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial

  22. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam Therapeutics

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  23. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

    IDEAYA Biosciences

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  25. An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Solid tumors and ovarian cancer

    phase 1 other active

    1 trial

  26. An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  27. An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

    AstraZeneca AB

    Breast Cancer

    phase 1 other active

    1 trial

  28. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  29. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib Tablets 100 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with Bosulif (bosutinib) 100 mg, Manufactured and Packed by: Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee, Freiburg, Germany, Imported by: Pfizer Brasil Ltda. Rodovia Presidente Castelo Branco, nº32501, km 32.5 CEP 06696-000 – Itapevi – SP, in healthy adult, huma

    Lacuna Pharma Pty Ltd

    myeloid leukemia

    phase 1 other active

    1 trial

  30. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 160 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subject

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  31. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 80 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  32. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  33. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec® (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo – SP, CNPJ: 56.994.

    Lacuna Pharma Pty Ltd

    Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid Leukemia

    phase 1 other active

    1 trial

  34. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code

    Lacuna Pharma Pty Ltd

    chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia

    phase 1 other active

    1 trial

  35. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  36. An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

    BioNTech SE

    Metastatic melanoma

    phase 1 other active

    1 trial

  37. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  38. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  39. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  40. Anti-CD123 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    AML (Acute Myeloid Leukemia)

    phase 1 small molecule active

    1 trial

  41. Anti-CD19 Universal CAR-T Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  42. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  43. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  44. Anti-CD5 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    T-ALL/Lymphoma

    phase 1 mab active

    1 trial

  45. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  46. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  47. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  48. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.